PMID- 27161868
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20220409
IS  - 1552-3365 (Electronic)
IS  - 0363-5465 (Linking)
VI  - 44
IP  - 8
DP  - 2016 Aug
TI  - The Properties of 3 Different Plasma Formulations and Their Effects on 
      Tendinopathic Cells.
PG  - 1952-61
LID - 10.1177/0363546516643814 [doi]
AB  - BACKGROUND: Tendinopathies are attributed to failure of the healing process and 
      inadequate tissue remodeling. Plasma injections can trigger regenerative 
      responses by modifying the molecular microenvironment. PURPOSE: To examine the 
      differences in the mitotic, chemotactic, anabolic, and inflammatory effects 
      between leukocyte- and platelet-rich plasma (L-PRP), platelet-rich plasma (PRP), 
      and platelet-poor plasma (PPP). STUDY DESIGN: Controlled laboratory study. 
      METHODS: Tendinopathic cells were cultured in 3-dimensional (3D) hydrogels formed 
      using PPP, PRP, and L-PRP. Cell migration was evaluated using a mu-Slide 
      chemotaxis chamber with video microscopy. Proliferation was assessed using XTT 
      assays. Expression of genes associated with matrix turnover, including type 1 
      collagen (COL1A1), COL3A1, aggrecan, decorin, fibronectin, matrix 
      metalloproteinase 1 (MMP-1), MMP-3, A Disintegrin-Like And Metalloprotease With 
      Thrombospondin Type 1 Motif proteins 4 (ADAMTS-4), and ADAMTS-5, was assessed 
      using real-time reverse-transcription polymerase chain reaction. Secreted 
      inflammatory proteins, including interleukin (IL)-1beta, IL-6, IL-8, monocyte 
      chemotactic protein 1 (MCP-1), and regulated on activation, normal T cell 
      expressed and secreted (RANTES), as well as vascular endothelial growth factor 
      (VEGF) and connective tissue growth factor (CTGF), were quantified using 
      enzyme-linked immunosorbent assay. RESULTS: Tendinopathic cells migrate at a 
      higher velocity along L-PRP and PRP than along PPP gradients. PRP and L-PRP 
      promote hypercellularity. PPP and PRP showed more pronounced anabolic properties, 
      as demonstrated by enhanced COL1A1 and COL3A1 and reduced MMP-1 expression. 
      Decorin, fibronectin, and aggrecan were downregulated in L-PRP compared with PPP 
      and PRP. L-PRP and PRP were shown to be more proinflammatory than PPP in terms of 
      IL-6 secretion, but cells in PPP showed MCP-1(high) phenotype. CTGF secretion was 
      significantly reduced in L-PRP compared with PPP and PRP. CONCLUSION: The main 
      advantages of L-PRP and PRP use, compared with PPP, include their stronger 
      chemotactic and proliferative properties. While PPP and PRP stimulate matrix 
      anabolism, L-PRP is more proinflammatory. Emphasis should be placed on the 
      temporal needs and biological characteristics of injured tendons, and plasma 
      formulations need to be tailored accordingly. CLINICAL RELEVANCE: Versatile 
      systems allowing the preparation of different plasma formulations, such as PPP, 
      PRP, or L-PRP, can help refine clinical applications by taking advantage of their 
      different biological properties.
CI  - (c) 2016 The Author(s).
FAU - Rubio-Azpeitia, Eva
AU  - Rubio-Azpeitia E
AD  - BioCruces Health Research Institute, Cruces University Hospital, Barakaldo, 
      Spain.
FAU - Bilbao, Ane M
AU  - Bilbao AM
AD  - Arthroscopic Surgery Unit Research, Hospital Vithas San Jose, Vitoria-Gasteiz, 
      Spain.
FAU - Sanchez, Pello
AU  - Sanchez P
AD  - Arthroscopic Surgery Unit Research, Hospital Vithas San Jose, Vitoria-Gasteiz, 
      Spain.
FAU - Delgado, Diego
AU  - Delgado D
AD  - Arthroscopic Surgery Unit Research, Hospital Vithas San Jose, Vitoria-Gasteiz, 
      Spain.
FAU - Andia, Isabel
AU  - Andia I
AD  - BioCruces Health Research Institute, Cruces University Hospital, Barakaldo, Spain 
      iandia2010@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160509
PL  - United States
TA  - Am J Sports Med
JT  - The American journal of sports medicine
JID - 7609541
RN  - 0 (Collagen Type I)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Adult
MH  - Collagen Type I/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Interleukin-1beta/metabolism
MH  - Interleukin-6/metabolism
MH  - Interleukin-8/metabolism
MH  - Leukocytes/metabolism
MH  - Male
MH  - Matrix Metalloproteinase 1/metabolism
MH  - Platelet-Rich Plasma/*chemistry
MH  - Tendinopathy/*drug therapy/metabolism/physiopathology
MH  - Tendons/drug effects/metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Wound Healing
OTO - NOTNLM
OT  - PPP
OT  - PRP
OT  - anabolism
OT  - chemotaxis
OT  - inflammation
OT  - leukocyte-rich PRP
OT  - tendinopathy
OT  - tissue healing
EDAT- 2016/05/11 06:00
MHDA- 2017/12/13 06:00
CRDT- 2016/05/11 06:00
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - 0363546516643814 [pii]
AID - 10.1177/0363546516643814 [doi]
PST - ppublish
SO  - Am J Sports Med. 2016 Aug;44(8):1952-61. doi: 10.1177/0363546516643814. Epub 2016 
      May 9.